Cancer treatment by intracellular hyperthermia
    5.
    发明授权
    Cancer treatment by intracellular hyperthermia 失效
    癌症治疗通过细胞内热疗

    公开(公告)号:US4569836A

    公开(公告)日:1986-02-11

    申请号:US497704

    申请日:1983-05-24

    申请人: Robert T. Gordon

    发明人: Robert T. Gordon

    摘要: A treatment of cancer by the application of chemical reactions intracellularly capable of the intracellular generation of heat so as to induce selective thermal death of cancer cells in living tissue. Metabolizable minute particles of a size less than one micron are intravenously injected into the patient and absorbed by the cancer cells. The oxygen level of the patient's blood is then increased. The rate of intracellular chemical reaction in the cancer cells due at least in part to the intracellular presence of these minute particles is thereby increased and intracellular heat generated. The oxygen level is increased until the intracellular temperature has increased at least 8.0 degrees Centigrade but not more than 9.5 degrees Centigrade thereby selectively killing the cancer cells without damaging the normal cells.

    摘要翻译: 通过应用细胞内产生热量的化学反应来治疗癌症,以诱导活体组织中癌细胞的选择性热死亡。 将尺寸小于1微米的可代谢的微小颗粒静脉内注射到患者体内并被癌细胞吸收。 然后增加患者血液的氧气含量。 由于至少部分地由于这些微小颗粒的细胞内存在而导致的癌细胞中的细胞内化学反应的速率由此增加并产生细胞内的热量。 增加氧水平直到细胞内温度升高至少8.0摄氏度但不超过9.5摄氏度,从而选择性地杀死癌细胞而不损害正常细胞。

    Particulate material
    7.
    发明授权
    Particulate material 失效
    颗粒材料

    公开(公告)号:US5885547A

    公开(公告)日:1999-03-23

    申请号:US676381

    申请日:1996-09-23

    摘要: A particulate material which comprises hollow or cup-shaped ceramic microspheres having a diameter in the range of from 5 to 200 microns. The material may comprise a beta- or gamma-emitting radionuclide and be used in selective internal radiation therapy (SIRT) of various forms of cancer and tumours.

    摘要翻译: PCT No.PCT / AU95 / 00027 Sec。 371日期1996年9月23日 102(e)日期1996年9月23日PCT提交1995年1月20日PCT公布。 第WO95 / 19841号公报 日期1995年7月27日一种颗粒材料,其包括直径在5至200微米范围内的中空或杯形陶瓷微球。 该材料可以包含β-或γ-发射放射性核素,并且可用于各种形式的癌症和肿瘤的选择性内部放射治疗(SIRT)。

    Composition and method for radiation synovectomy of arthritic joints
    9.
    发明授权
    Composition and method for radiation synovectomy of arthritic joints 失效
    关节炎关节放射性滑膜切除术的组成和方法

    公开(公告)号:US5039326A

    公开(公告)日:1991-08-13

    申请号:US408087

    申请日:1989-09-15

    IPC分类号: A61K9/16 A61K51/12

    摘要: A method for preparing nonradioactive microspheres adapted for radiation synovectomy of arthritic joints in a mammal involves forming the microspheres by doping a biodegradable glass material which may be lithium or potassium silicate, lithium or potassium aluminosilicate, lithium or potassium aluminoborate, lithium or potassium germanate or lithium or potassium aluminogermanate with an isotope which may be samarium, holmium, erbium, dysprosium, rhemium or yttrium so that the isotope is chemcially dissolved in and distributed uniformly throughout the glass material. The doped glass material is then treated with an acid wash to produce a thin layer on the surface thereof and heat treated to improve the chemical durability of the glass material by rendering the solubility of the layer lower than that of the underlying glass material.

    摘要翻译: 适用于哺乳动物关节炎关节放射性滑膜切除术的非放射性微球的方法包括通过掺入可生物降解的玻璃材料来形成微球,所述可生物降解的玻璃材料可以是硅酸锂或硅酸钾,铝硅酸锂或钾,铝硼酸锂或钾,锗酸锂或钾, 或具有可能是钐,钬,铒,镝,铼或钇的同位素的铝锗酸钾,使得同位素化学溶解并均匀分布在整个玻璃材料中。 然后将掺杂的玻璃材料用酸洗处理以在其表面上产生薄层并进行热处理,以通过使层的溶解度低于下层玻璃材料的溶解度来改善玻璃材料的化学耐久性。

    Diagnostic agent
    10.
    发明授权
    Diagnostic agent 失效
    诊断代理

    公开(公告)号:US4126669A

    公开(公告)日:1978-11-21

    申请号:US767197

    申请日:1977-02-09

    摘要: A diagnostic agent for intravascular administration into blood vessels composed of radioactively labelled particles suspended in a physiologically acceptable aqueous liquid, said particles having a size so selected that they clog fine blood vessels having a diameter within the range 5 - 300 .mu.m, said particles consisting of a three-dimensional, water-insoluble, hydrophilic, swellable, cross-linked network of polysaccharide substances, and the method of using this diagnostic agent.